Illumina had its Relative Strength (RS) Rating upgraded from 65 to 71 Monday — a welcome improvement, but still shy of the 80 or higher score you prefer to see.
This exclusive rating from Investor's Business Daily identifies share price action with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the last 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the market's biggest winners typically have an RS Rating of over 80 as they launch their largest price moves. See if Illumina can continue to show renewed price strength and hit that benchmark.
How To Invest In Stocks In Both Bull And Bear Markets
Illumina is trying to complete a consolidation with a 156.66 entry. See if it can break out in heavy trade.
Top and bottom line growth moved higher last quarter. Earnings were up 245%, compared to 13% in the prior report. Revenue increased from -5% to -3%.
The company earns the No. 6 rank among its peers in the Medical-Research Equipment/Services industry group. Veracyte, Natera and Medpace Holdings are among the top 5 highly rated stocks within the group.
RELATED:
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
